Novo Nordisk A/S (NYSE:NVO) Position Trimmed by Fmr LLC

FMR LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 44.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,021,884 shares of the company's stock after selling 7,909,693 shares during the quarter. FMR LLC owned approximately 0.22% of Novo Nordisk A/S worth $862,082,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the business. GQG Partners LLC increased its holdings in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after buying an additional 5,556,460 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $404,910,000. Loomis Sayles & Co. L P raised its position in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Clearbridge Investments LLC lifted its stake in Novo Nordisk A/S by 59.8% during the fourth quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock worth $368,451,000 after purchasing an additional 1,602,549 shares during the last quarter. Finally, Sustainable Growth Advisers LP boosted its holdings in Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock worth $459,416,000 after purchasing an additional 1,021,498 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research firms recently weighed in on NVO. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Monday. Finally, Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded up $3.20 during midday trading on Friday, reaching $64.41. 6,219,187 shares of the company were exchanged, compared to its average volume of 5,770,327. The company's 50 day moving average price is $78.23 and its two-hundred day moving average price is $93.98. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market cap of $289.02 billion, a P/E ratio of 19.60, a PEG ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a 12 month low of $59.32 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a $0.7874 dividend. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is 49.54%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.